vs
COMSCORE, INC.（SCOR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是COMSCORE, INC.的1.4倍（$127.1M vs $93.5M），再鼎医药同比增速更快（17.1% vs -1.5%），COMSCORE, INC.自由现金流更多（$2.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 3.8%）
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SCOR vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$93.5M
营收增速更快
ZLAB
高出18.7%
-1.5%
自由现金流更多
SCOR
多$29.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $93.5M | $127.1M |
| 净利润 | $3.0M | — |
| 毛利率 | 41.0% | 51.0% |
| 营业利润率 | 7.0% | -54.6% |
| 净利率 | 3.2% | — |
| 营收同比 | -1.5% | 17.1% |
| 净利润同比 | -3.7% | — |
| 每股收益（稀释后） | $9.50 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SCORZLAB
| Q4 25 | $93.5M | $127.1M | ||
| Q3 25 | $88.9M | $115.4M | ||
| Q2 25 | $89.4M | $109.1M | ||
| Q1 25 | $85.7M | $105.7M | ||
| Q4 24 | $94.9M | $108.5M | ||
| Q3 24 | $88.5M | $101.8M | ||
| Q2 24 | $85.8M | $100.1M | ||
| Q1 24 | $86.8M | $87.1M |
净利润SCORZLAB
| Q4 25 | $3.0M | — | ||
| Q3 25 | $453.0K | $-36.0M | ||
| Q2 25 | $-9.5M | $-40.7M | ||
| Q1 25 | $-4.0M | $-48.4M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $-60.6M | $-41.7M | ||
| Q2 24 | $-1.7M | $-80.3M | ||
| Q1 24 | $-1.1M | $-53.5M |
毛利率SCORZLAB
| Q4 25 | 41.0% | 51.0% | ||
| Q3 25 | 40.6% | 59.5% | ||
| Q2 25 | 40.6% | 60.6% | ||
| Q1 25 | 39.6% | 63.6% | ||
| Q4 24 | 42.4% | 61.5% | ||
| Q3 24 | 41.2% | 64.1% | ||
| Q2 24 | 39.5% | 64.9% | ||
| Q1 24 | 42.3% | 61.4% |
营业利润率SCORZLAB
| Q4 25 | 7.0% | -54.6% | ||
| Q3 25 | 1.9% | -42.3% | ||
| Q2 25 | -1.9% | -50.3% | ||
| Q1 25 | -2.4% | -53.3% | ||
| Q4 24 | 4.1% | -62.6% | ||
| Q3 24 | -67.4% | -66.6% | ||
| Q2 24 | -2.2% | -76.0% | ||
| Q1 24 | -2.2% | -80.7% |
净利率SCORZLAB
| Q4 25 | 3.2% | — | ||
| Q3 25 | 0.5% | -31.2% | ||
| Q2 25 | -10.6% | -37.3% | ||
| Q1 25 | -4.7% | -45.8% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | -68.5% | -40.9% | ||
| Q2 24 | -2.0% | -80.2% | ||
| Q1 24 | -1.2% | -61.4% |
每股收益（稀释后）SCORZLAB
| Q4 25 | $9.50 | $-0.05 | ||
| Q3 25 | $-0.86 | $-0.03 | ||
| Q2 25 | $-2.73 | $-0.04 | ||
| Q1 25 | $-1.66 | $-0.04 | ||
| Q4 24 | $-0.47 | $-0.09 | ||
| Q3 24 | $-12.79 | $-0.04 | ||
| Q2 24 | $-1.19 | $-0.08 | ||
| Q1 24 | $-1.08 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.6M | $689.6M |
| 总债务越低越好 | $41.5M | — |
| 股东权益账面价值 | $111.4M | $715.5M |
| 总资产 | $407.7M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资SCORZLAB
| Q4 25 | $23.6M | $689.6M | ||
| Q3 25 | $26.7M | $717.2M | ||
| Q2 25 | $26.0M | $732.2M | ||
| Q1 25 | $31.0M | $757.3M | ||
| Q4 24 | $29.9M | $779.7M | ||
| Q3 24 | $20.0M | $616.1M | ||
| Q2 24 | $14.7M | $630.0M | ||
| Q1 24 | $18.7M | $650.8M |
总债务SCORZLAB
| Q4 25 | $41.5M | — | ||
| Q3 25 | $41.4M | — | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $41.3M | — | ||
| Q4 24 | $41.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SCORZLAB
| Q4 25 | $111.4M | $715.5M | ||
| Q3 25 | $-26.3M | $759.9M | ||
| Q2 25 | $-21.7M | $791.7M | ||
| Q1 25 | $-13.5M | $810.8M | ||
| Q4 24 | $-8.3M | $840.9M | ||
| Q3 24 | $-2.7M | $667.7M | ||
| Q2 24 | $45.8M | $704.2M | ||
| Q1 24 | $51.4M | $762.2M |
总资产SCORZLAB
| Q4 25 | $407.7M | $1.2B | ||
| Q3 25 | $406.9M | $1.2B | ||
| Q2 25 | $415.9M | $1.2B | ||
| Q1 25 | $421.5M | $1.2B | ||
| Q4 24 | $430.2M | $1.2B | ||
| Q3 24 | $412.5M | $985.3M | ||
| Q2 24 | $474.1M | $987.4M | ||
| Q1 24 | $477.7M | $988.4M |
负债/权益比SCORZLAB
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $2.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 3.1% | -21.0% |
| 资本支出强度资本支出/营收 | 0.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.07× | — |
| 过去12个月自由现金流最近4个季度 | $21.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SCORZLAB
| Q4 25 | $3.2M | $-26.0M | ||
| Q3 25 | $9.5M | $-32.0M | ||
| Q2 25 | $932.0K | $-31.0M | ||
| Q1 25 | $9.1M | $-61.7M | ||
| Q4 24 | $-10.0M | $-55.8M | ||
| Q3 24 | $12.5M | $-26.8M | ||
| Q2 24 | $8.7M | $-42.2M | ||
| Q1 24 | $6.9M | $-90.1M |
自由现金流SCORZLAB
| Q4 25 | $2.9M | $-26.7M | ||
| Q3 25 | $9.4M | $-35.0M | ||
| Q2 25 | $787.0K | $-33.9M | ||
| Q1 25 | $8.7M | $-63.2M | ||
| Q4 24 | $-10.3M | $-58.4M | ||
| Q3 24 | $12.4M | $-28.2M | ||
| Q2 24 | $8.5M | $-42.9M | ||
| Q1 24 | $6.6M | $-91.1M |
自由现金流率SCORZLAB
| Q4 25 | 3.1% | -21.0% | ||
| Q3 25 | 10.5% | -30.4% | ||
| Q2 25 | 0.9% | -31.1% | ||
| Q1 25 | 10.1% | -59.9% | ||
| Q4 24 | -10.8% | -53.8% | ||
| Q3 24 | 14.0% | -27.7% | ||
| Q2 24 | 10.0% | -42.9% | ||
| Q1 24 | 7.6% | -104.5% |
资本支出强度SCORZLAB
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.4% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
现金转化率SCORZLAB
| Q4 25 | 1.07× | — | ||
| Q3 25 | 20.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
